Company intelligence / Profile preview

杭州中美华东制药有限公司 (Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.)

Ownership: Public · 000963
Employees: ~9000
Development stage: Commercial

Overview

中美华东制药是中国领先的综合性医药企业，专注于创新和仿制药物的研发、生产与销售。其产品覆盖移植免疫、内分泌、慢性肾病、消化系统、抗生素、抗肿瘤及心血管等领域。公司拥有多个通过FDA/TGA/EU COS认证的生产基地，部分创新项目处于临床开发阶段（如GLP‑1/GIP双激动剂SCO‑094），并有多款产品已商业化上市。

Therapeutic areas: Metabolic DisordersOncologyEndocrinologyImmunologyGastroenterologyCardiovascularNephrology
Modalities: Small moleculesbiologicspeptidestraditional Chinese medicine productsbiosimilars
Industry: Biotech

Drug pipeline

3 assets

HDM2005

IND

Indications: Mantle cell lymphoma

2 more assets in the full pipeline.

Request access →

Partnerships

SCOHIA PHARMA Inc. （日本，SCO–094全球独家开发权）Heidelberg Pharma 等国际合作伙伴。

Beyond the preview

Go deeper on 杭州中美华东制药有限公司 (Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.).

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 杭州中美华东制药有限公司 (Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.).

Explore the full profile